Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ) is now available.
NeuroScientific Biopharmaceuticals has received approval from the Therapeutic Goods Administration (TGA) for the first three patients in a special access program using its StemSmart™ technology for treating fistulising Crohn’s disease. This milestone is significant as it marks progress towards a Phase 2 clinical trial and demonstrates the potential of StemSmart™ in addressing severe cases of Crohn’s disease. The company’s collaboration with Q-Gen Cell Therapeutics for manufacturing scalability and the anticipated expansion of patient recruitment highlight its strategic positioning in the market. The successful implementation of this program could have implications for broader applications in Crohn’s disease and other conditions, potentially impacting the global market for stem cell therapies.
More about Neuroscientific Biopharmaceuticals Ltd.
NeuroScientific Biopharmaceuticals Limited is an Australian biotechnology company focused on developing novel technologies for immune-mediated inflammatory diseases. The company is known for its innovative approaches in the biopharmaceutical industry, particularly in the development of stem cell therapies.
Average Trading Volume: 551,277
Technical Sentiment Signal: Buy
Current Market Cap: A$51.55M
For an in-depth examination of NSB stock, go to TipRanks’ Overview page.